Particle Sciences, CHEMO in Hormone Development Pact

Particle Sciences, Inc. (PSI) and CHEMO have partnered to offer development and commercial manufacturing services for hormone-eluting devices. Particle Sciences provides formulation, testing and scaleup of drug/device combinations and has been working with CHEMO for several years on a number of hormone-based polymeric combination products.  

Particle Sciences will conduct the development work, establish design, performance, scaleup parameters, analytic and QC methods and produce clinical trial materials. CHEMO will assume production and fulfillment roles in mid-to-late clinical testing and through to commercialization.  

Mark Mitchnick, chief executive officer of Particle Sciences, commented, “In our work with CHEMO and others, it became clear that there was no complete solution for companies wishing to develop and commercialize hormone-based combination products. CHEMO is basic in many hormones, a well-respected global supplier, and has strong global marketing capabilities in WHC. Particle Sciences has the intellectual property, infrastructure and development capabilities to rapidly get such products into the clinic. By combining our efforts, CHEMO and Particle Sciences now offer the only complete solution for combination product development.”

Lucas Sigman, chief executive officer of Chemo’s U.S. Subsidiary, said, “Particle Sciences has a top tier technical team and an excellent facility. This relationship is yet another step in CHEMO’s global technology-based expansion. As an API supplier and FDF manufacturer, bringing in hormone-based combination product capabilities is a natural step and one that we are very enthusiastic about.”